Capecitabine and trastuzumab emtansine are standard treatments for patients with residual triple-negative and HER2+ breast cancer after neoadjuvant standard treatment, respectively, based on escalation studies in patients with non-pathological clinical response after neoadjuvant CT as the standard regimen [14, 15]. The gene discussed is ERBB2; the disease is breast carcinoma.